COX-2 inhibitors in cancer treatment and prevention, a recent development.
about
Hepatitis C Virus Stimulates the Expression of Cyclooxygenase-2 via Oxidative Stress: Role of Prostaglandin E2 in RNA ReplicationAspirin use and lung cancer in menNon steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and realityAspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cellsLung Krüppel-like factor (LKLF) is a transcriptional activator of the cytosolic phospholipase A2 alpha promoterPhase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.Contrast enhanced maximum intensity projection ultrasound imaging for assessing angiogenesis in murine glioma and breast tumor models: A comparative study.Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention.Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.Metabolic syndrome and cancerSuppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin.COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.Expression of cyclooxygenase-2 (COX-2) in pituitary tumours.Immunohistochemical expression of COX2 and iNOS in bladder cancer and its association with urinary schistosomiasis among Sudanese patientsComparable molecular alterations in 4-nitroquinoline 1-oxide-induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients.Cyclooxygenase-2 expression in animal cancers.HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis.Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitis.Relationship between tumour angiogenesis and expression of cyclo-oxygenase-2 and vascular endothelial growth factor-A in human renal cell carcinoma.Diclofenac-induced apoptosis in the neuroblastoma cell line SH-SY5Y: possible involvement of the mitochondrial superoxide dismutaseMonitoring angiogenesis in human melanoma xenograft model using contrast-enhanced ultrasound imaging.NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2.Inflammation and cancer.Antitumor effect of retinoic acid receptor-beta2 associated with suppression of cyclooxygenase-2.Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins.A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis.Radioprotective effect of mefenamic acid against radiation-induced genotoxicity in human lymphocytes.Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.The shape/morphology balance: a study of stealth liposomes via fractal analysis and drug encapsulation.Clinical activity of celecoxib in metastatic malignant melanoma.Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden.Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats.COX-(2) overexpression in sinonasal inverted papilloma.Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation.Synthesis of 18F-labelled cyclooxygenase-2 (COX-2) inhibitors via Stille reaction with 4-[18F]fluoroiodobenzene as radiotracers for positron emission tomography (PET).A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells.
P2860
Q27470314-16B23A0E-55CC-4AA7-A158-E89CABC187B2Q28165856-258A0F45-90B1-4D03-A2D7-BF48A682B8F5Q28166312-F9E519AF-00B2-42BA-A8ED-770DD4F1140DQ28193816-9D6E4F2A-6FAA-405E-B23A-997779D56D7EQ28383522-09765A9F-43BF-427F-8ABD-BEF3187650D6Q28565657-EE9FD51D-1FFF-4037-8EFA-9D4ED8EDA79DQ34016435-A67BFB2F-30E1-4C5D-B2CE-FCDAAF88D594Q34536116-0C5A1D8E-1075-40D9-BCE7-B1ADAB447F2EQ35010488-74DA8E70-B550-4CEB-9AFF-436C0F0404CCQ35011895-D9001E61-5236-44D1-96EC-8E8E3C7D6384Q35220347-67C3B242-E63E-4AE3-B7A2-AF3AF8001C5AQ35319301-C5C6A480-2303-49CC-B684-793682D90E42Q35670438-E54C2183-D40E-46B1-B9DE-B9FAC5FB5564Q35753467-E96BD331-1A6F-4158-B243-C6EF63E78C76Q36271954-02DDD92D-7786-4F27-B806-ED60C9E0E6F0Q36577742-D8FBEFC7-394F-48C1-B5B1-11CDC589CEF3Q36690921-E57D7DF5-5BA3-4963-950D-8F943053EBD0Q37362098-23884BCF-E30B-4EE6-8177-08CDB805E3F6Q37793667-A6AE9D86-C26A-4FD4-814F-BEFCD78F4EC6Q37948622-A971DC86-94C1-4F0B-93A6-D7A4BF92C2E7Q38335547-5EBBCBBE-8464-411E-866E-11288EF40C24Q38388872-975D0BCC-6417-43A7-98B6-16F50C128105Q39681111-8A619AF5-D9EC-415D-8EF2-0F10E8019F9BQ39840949-18E291AF-E2F2-4815-802A-94675CF52E58Q39892364-4CB50621-DA6A-412B-9D3B-F1D9C5373401Q41853728-CF09398E-2833-4813-AC91-27FF795551FEQ42269301-0296D13F-29DA-43E1-ACCB-A7308F5F2147Q43011006-DE3879E2-0581-4EA1-B7D1-A0C85E20AF82Q43060768-2CEE57D8-BB31-4892-8820-E64FDB51B0AFQ43187352-B0DE38AE-ACBF-490D-A60D-FC53A934D3C1Q43217946-3F88F01F-7562-4D15-97C3-F3AA74C5A902Q43670982-EA3640E6-29B1-4760-835B-B99D6F2B84A7Q43801386-9AAA8D52-3546-45DA-B925-E5C7363E2066Q45076856-C637830A-38FA-4B12-9B9F-E106E29D9C43Q46816587-A8499B8F-CE46-453F-8F45-D904D12CD49BQ46888790-231A4352-7263-45CA-89EC-25A63403CF2DQ46929693-F992BD77-9000-416F-9684-1602C94D321CQ53241704-40E12CD5-93B1-48FF-85F1-7DCBF667E094Q53596493-1EAE0501-8CD1-448B-8653-14910366F954Q55012542-49A910B9-41AC-4378-BCA5-5B1EFA772D21
P2860
COX-2 inhibitors in cancer treatment and prevention, a recent development.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@ast
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@en
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@nl
type
label
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@ast
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@en
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@nl
prefLabel
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@ast
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@en
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@nl
P1433
P1476
COX-2 inhibitors in cancer treatment and prevention, a recent development.
@en
P2093
Xiao-Chun Xu
P304
P356
10.1097/00001813-200202000-00003
P577
2002-02-01T00:00:00Z